Home / Japan / Oncolys BioPharma Inc.
Oncolys BioPharma Inc.
Short position disclosed on October 30, 2026.
10.56% of the capital sold short
7 disclosing funds
172 disclosures on record
Evolution of the disclosed total
0%5%10%15%
Aug 22Sep 9Sep 27Oct 15Nov 2
Open positions
| Fund | Twelve months | % of capital | Over the year | Since |
|---|---|---|---|---|
| Barclays Capital Securities Ltd | 2.70% | -1.95 pt | October 29, 2026 | |
| Goldman Sachs International | 2.57% | new | October 29, 2026 | |
| モルガン・スタンレーmufg証券株式会社 | 1.94% | -4.33 pt | October 30, 2026 | |
| Citigroup Global Markets Limited | 1.21% | new | October 29, 2026 | |
| JPM Securities Japan Co Ltd. | 0.83% | new | October 29, 2026 | |
| UBS AG | 0.80% | -0.52 pt | October 29, 2026 | |
| Jane Street Asia Trading Limited | 0.51% | new | October 29, 2026 |
Get the moves on Oncolys BioPharma Inc. by mail, at most once a day.
There is no account to create. You give an address, you confirm it through a link, and every message contains a link to stop.
History of disclosures
Download 172 filings as CSV Columns: Date, Fund, Market, Disclosed position, Unit, End date. The other formats
Other companies sold short in Japan
- QD Laser,Inc. 15.12% of the capital sold short
- Datasection Inc. 12.66% of the capital sold short
- KLab Inc. 12.14% of the capital sold short
- AIMECHATEC,Ltd. 9.64% of the capital sold short
- Kyoritsu Maintenance Co.,ltd. 9.45% of the capital sold short
- SHIFT Inc. 8.79% of the capital sold short
- ReYuu Japan Inc. 8.43% of the capital sold short
- Astroscale Holdings Inc. 8.35% of the capital sold short
- Pacific Metals Co.,ltd. 7.68% of the capital sold short
- Nissan Motor Co.,ltd. 7.27% of the capital sold short
- Dynamic Map Platform Co.,Ltd. 7.23% of the capital sold short
- GNI Group Ltd. 6.91% of the capital sold short
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Oncolys BioPharma Inc., source JPX, data as at October 30, 2026, https://www.quivad.com/action/oncolys-biopharma-inc?page=3